MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Christophe has run MedinCell since 2009, when it was eight people in a converted garage. Today it's one of only three French biotechs to ever cross $1B on Euronext.With one Teva-partnered product already a commercial success, the partners are potentially weeks away from getting FDA approval for a second.We also talked about France’s biotech giants, the landscape of long-acting injectables, and why Christophe was once in charge of a remote fishing lodge in Canada.---Discover the best biotech companies in 🇪🇺 with the FlotBio Map at https://bit.ly/4nXmKjN--- ⭐️ ABOUT THE SPEAKER Before his time as CEO of MedinCell, Christophe was lead investor in Nanobiotix and served in roles at the Boston Consulting Group, and Matignon Investissement & Gestion.He also spent 15 years in North America, and he holds an engineering degree from École des Mines de Paris, a Master’s degree from the University of Minnesota, and an MBA from the University of Calgary. 🔗 LINKS MENTIONED Christophe Douat LinkedIn profile — https://www.linkedin.com/in/christophe-douat-16268a/ MedinCell — medincell.com Teva — tevapharm.com Uzedy FDA approval, April 2023 — https://www.tevausa.com/news-and-media/press-releases/teva-and-medincell-announce-fda-approval-of-uzedy-risperidone-extended-release-injectable-suspension-/ MedinCell investor presentation, Sept 2026 — https://www.medincell.com/wp-content/uploads/2026/09/Investors-Sept2026.pdf Pascal Touchon, Flot.bio E49 — https://flot.bio/episode/pascal-touchon-jeito/ Fredrik Tiberg, Flot.Bio E51 (Camurus) — https://flot.bio/episode/fredrik-tiberg-camurus-opioid-crisis/ Laurent Levy, Flot.Bio E45 (Nanobiotix) — https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/ Marc de Garidel, Flot.Bio E46 (Abivax) — https://flot.bio/episode/marc-de-garidel-abivax-ulcerative-colitis-inflammation/ Michel Vert, University of Montpellier — https://ibmm.umontpellier.fr/en/annuaire/vert-michel-2/ Teva completes Actavis Generics acquisition, 2016 — https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2016/Teva-Completes-Acquisition-of-Actavis-Generics/default.aspx J&J acquires Intra-Cellular Therapies, $14.6B — https://www.jnj.com/media-center/press-releases/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-therapies-inc 📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/medincell-french-biotech-giants/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmH LinkedIn: https://www.linkedin.com/company/flot-bio/ X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.Bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:03:05] Jeito’s Pascal Touchon: a Mutual Friend [00:05:35] Uzedy and Long-Acting Injectable Olanzapine: the Commercial Drive [00:07:42] How MedinCell Could Succeed with Olanzapine LAI Where Eli Lilly Failed [00:16:57] Camurus and MedinCell: European Champions in Long-Acting Injectables [00:20:51] Montpellier and the Foundation of MedinCell [00:25:19] Teva Pharmaceuticals: an Agile Partner [00:30:08] Nanobiotix and France’s $1B Market Cap Club [00:36:39] Contraception, Malaria and Schizophrenia: the Human Factor [00:46:05] From a Fishing Lodge in Ontario to Biotech CEO [00:51:10] Quick-Fire Questions